Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Financial Results (Feb 20, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 20, 2025
Period End
February 20, 2025
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed February 20, 2025. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) furnished a Form 8-K on February 20, 2025 reporting its fourth quarter and full year 2024 financial results and a commercial update on Attruby (acoramidis).

As of February 17, 2025, 1,028 unique patient prescriptions for Attruby had been written by 516 unique prescribers since FDA approval on November 22, 2024. Full year 2024 revenue was $221.9 milliona, up from $9.3 million in 2023, driven mainly by $207.7 million recognized from upfront payments and services revenue under the Bayer and Kyowa Kirin agreements, plus $2.9 million in net product revenue from Attruby. Net loss attributable to common stockholders of BridgeBio was $535.8 million for the year, or $2.88 per share, compared with $643.2 million, or $3.95 per share, in 2023.

Cash, cash equivalents and short-term restricted cash totaled $681.2 millionb at December 31, 2024, and net cash used in operating activities was $520.7 million for the year. The company also highlighted a European approval of acoramidis as BEYONTTRA on February 10, 2025, which triggered a $75 million milestone payment, and expects $105 million in regulatory milestones in the first half of 2025 from acoramidis approvals in Europe and Japan. Three Phase 3 studies (FORTIFY, CALIBRATE and PROPEL 3) are fully enrolled, with last participant last visit expected in 2025 before year-end.

Cash-flow financing during 2024 included a $488.8 millionc net Funding Agreement, $434.0 million net term loan proceeds, and $314.7 million from equity offerings. The filing is furnished under Item 2.02 and is not deemed filed for Section 18 purposes. Operating costs rose to $814.9 million in 2024 from $616.7 million, largely from a $138.3 million increase in SG&A tied to the Attruby launch, and the year included $25.0 million of nonrecurring deal-related costs.

Key Highlights

  1. Full year 2024 revenue of $221.9 million, versus $9.3 million in 2023, primarily from $207.7 million of upfront and service revenue under the Bayer and Kyowa Kirin agreements
  2. Attruby (acoramidis) has 1,028 unique patient prescriptions from 516 unique prescribers as of February 17, 2025, since FDA approval on November 22, 2024
  3. Acoramidis approved in the EU as BEYONTTRA on February 10, 2025, with a $75 million milestone payment and tiered royalties beginning in the low-thirties percent
  4. Company expects $105 million in regulatory milestones in 1H 2025 from acoramidis approvals in Europe and Japan
  5. Net loss attributable to common stockholders of $535.8 million for 2024 ($2.88 per share), compared with $643.2 million ($3.95 per share) in 2023
  6. Cash, cash equivalents and short-term restricted cash of $681.2 million at December 31, 2024; net cash used in operating activities of $520.7 million for the year
  7. FORTIFY (BBP-418), CALIBRATE (encaleret) and PROPEL 3 (infigratinib) Phase 3 studies are fully enrolled, with last participant last visit expected before the end of 2025

Frequently Asked Questions

  1. How is Attruby's commercial launch progressing?

    As of February 17, 2025, 1,028 unique patient prescriptions had been written by 516 unique prescribers since FDA approval on November 22, 2024. In 2024, Attruby generated $2.9 million in net product revenue following its first U.S. commercial sales. SG&A expenses rose $138.3 million for the year, mainly to support the launch, including marketing and a U.S. sales force.

  2. What drove the increase in 2024 revenue?

    Revenue was $221.9 million for 2024 versus $9.3 million in 2023. The filing attributes $207.7 million to recognition of upfront payments and service revenue under the exclusive license and collaboration agreements with Bayer and Kyowa Kirin, and $2.9 million to net product revenue from Attruby.

  3. How did the company fund its operations in 2024?

    Financing inflows included $488.8 million in net proceeds from the Funding Agreement, $434.0 million in net proceeds from a term loan, and $314.7 million from various equity financings. These offset $520.7 million of net cash used in operating activities and $473.4 million used to refinance the previous senior secured term loan, including prepayment fees and exit-related costs. Cash, cash equivalents and short-term restricted cash ended the year at $681.2 million.

  4. What are the near-term regulatory and clinical catalysts?

    The company expects $105 million in regulatory milestones in the first half of 2025 from acoramidis approvals in Europe and Japan, and Japan approval is expected in 1H 2025. For BBP-418, encaleret and infigratinib in achondroplasia, last participant last visit is expected in 2H 2025, with topline results for BBP-418 and encaleret also expected in 2H 2025.

  5. What drove the change in operating expenses and the net loss?

    Operating costs and expenses rose to $814.9 million in 2024 from $616.7 million, with R&D expenses up $52.2 million and restructuring, impairment and related charges up $7.7 million. Operating costs include $25.0 million of nonrecurring deal-related costs. Net loss attributable to common stockholders narrowed to $535.8 million from $643.2 million, partly due to a $178.3 million gain on deconsolidation of subsidiaries.